Inge Lefevre

1.8k total citations
22 papers, 274 citations indexed

About

Inge Lefevre is a scholar working on Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Inge Lefevre has authored 22 papers receiving a total of 274 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 11 papers in Epidemiology and 9 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Inge Lefevre's work include Mosquito-borne diseases and control (9 papers), Bacterial Infections and Vaccines (8 papers) and Pneumonia and Respiratory Infections (7 papers). Inge Lefevre is often cited by papers focused on Mosquito-borne diseases and control (9 papers), Bacterial Infections and Vaccines (8 papers) and Pneumonia and Respiratory Infections (7 papers). Inge Lefevre collaborates with scholars based in Switzerland, United States and Philippines. Inge Lefevre's co-authors include Derek Wallace, Hans L. Bock, Martina Rauscher, Astrid Borkowski, Vianney Tricou, Manja Brose, Salvacion Gatchalian, Xavier Sáez‐Llorens, Peter Winkle and Marie‐Pierre David and has published in prestigious journals such as The Lancet, Vaccine and American Journal of Tropical Medicine and Hygiene.

In The Last Decade

Inge Lefevre

21 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Inge Lefevre Switzerland	10	158	156	100	54	43	22	274
Chee‐Fu Yung Singapore	6	187 1.2×	182 1.2×	100 1.0×	20 0.4×	16 0.4×	8	337
Angkool Kerdpanich Thailand	9	203 1.3×	169 1.1×	68 0.7×	25 0.5×	16 0.4×	15	279
Luis Rivera United States	11	219 1.4×	230 1.5×	144 1.4×	10 0.2×	76 1.8×	22	410
Varja Grabovac Philippines	10	229 1.4×	99 0.6×	87 0.9×	19 0.4×	28 0.7×	23	316
Diane van der Vliet France	10	149 0.9×	143 0.9×	57 0.6×	19 0.4×	12 0.3×	17	253
Alix Collard Belgium	12	115 0.7×	68 0.4×	180 1.8×	140 2.6×	23 0.5×	15	369
Joseph Biey Republic of the Congo	8	99 0.6×	71 0.5×	91 0.9×	27 0.5×	24 0.6×	13	208
Darlene Baxendale Canada	5	265 1.7×	239 1.5×	139 1.4×	60 1.1×	8 0.2×	5	388
Sergey Diorditsa Philippines	9	126 0.8×	94 0.6×	162 1.6×	5 0.1×	110 2.6×	11	290
В. В. Романенко Russia	8	131 0.8×	91 0.6×	137 1.4×	17 0.3×	16 0.4×	34	258

Countries citing papers authored by Inge Lefevre

Since Specialization

Citations

This map shows the geographic impact of Inge Lefevre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge Lefevre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge Lefevre more than expected).

Fields of papers citing papers by Inge Lefevre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge Lefevre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge Lefevre. The network helps show where Inge Lefevre may publish in the future.

Co-authorship network of co-authors of Inge Lefevre

This figure shows the co-authorship network connecting the top 25 collaborators of Inge Lefevre. A scholar is included among the top collaborators of Inge Lefevre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge Lefevre. Inge Lefevre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fernando, LakKumar, Pujitha Wickramasinghe, Asvini D. Fernando, et al.. (2024). Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience. PLoS neglected tropical diseases. 18(8). e0012376–e0012376. 3 indexed citations

Tricou, Vianney, Paul Collini, Martina Rauscher, et al.. (2023). A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine. 41(7). 1398–1407. 11 indexed citations

Patel, Sanjay S., et al.. (2023). An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life. Human Vaccines & Immunotherapeutics. 19(2). 2254964–2254964. 20 indexed citations

Tricou, Vianney, Brandon Essink, John Ervin, et al.. (2023). Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS neglected tropical diseases. 17(3). e0011124–e0011124. 16 indexed citations

Sáez‐Llorens, Xavier, Shibadas Biswal, Charissa Borja-Tabora, et al.. (2023). Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue. American Journal of Tropical Medicine and Hygiene. 108(4). 722–726. 14 indexed citations

Lefevre, Inge, Lulu Bravo, Nicolas Folschweiller, et al.. (2023). Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. npj Vaccines. 8(1). 75–75. 8 indexed citations

Tricou, Vianney, Peter Winkle, Leslie Tharenos, et al.. (2023). Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults. Vaccine. 41(47). 6999–7006. 7 indexed citations

Tricou, Vianney, Xavier Sáez‐Llorens, Delia Yu, et al.. (2020). Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. The Lancet. 395(10234). 1434–1443. 66 indexed citations

Lefevre, Inge, et al.. (2018). 2276. Immunogenicity of Takeda’s Bivalent Virus-Like Particle (VLP) Norovirus Vaccine (NoV) Candidate in Children From 6 Months up to 4 Years of Age. Open Forum Infectious Diseases. 5(suppl_1). S674–S674. 9 indexed citations

10.

Burgess, Margaret A, Peter McIntyre, Margaret Hellard, et al.. (2010). Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 28(10). 2222–2226. 17 indexed citations

11.

Espinoza, Félix, Miguel Tregnaghi, Ángela Gentile, et al.. (2010). Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial. BMC Infectious Diseases. 10(1). 297–297. 11 indexed citations

12.

Gatchalian, Salvacion, Gunasekaran Ramakrishnan, Hans L. Bock, Inge Lefevre, & Jeanne‐Marie Jacquet. (2010). Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen contentHaemophilus influenzaetype b vaccine in Filipino children. Human Vaccines. 6(8). 664–672. 3 indexed citations

13.

Damme, Pierre Van, Frank von Sonnenburg, Christoph Hatz, et al.. (2009). Long‐term immunogenicity of preservative‐free hepatitis B vaccine formulations in adults. Journal of Medical Virology. 81(10). 1710–1715. 5 indexed citations

14.

Gatchalian, Salvacion, Nancy Bermal, Vijayalakshmi Chandrasekaran, et al.. (2008). A new DTPw-HBV/Hib vaccine: Immune memory after primary vaccination and booster dosing in the second year of life. Human Vaccines. 4(1). 60–66. 7 indexed citations

15.

Таточенко, В. К., С. М. Харит, Igor Smolenov, et al.. (2008). Co-Administration of a Human Rotavirus Vaccine Rix4414 with DTPw-HBv Vaccines: Immunogenicity and Reactogenicity in Healthy Infants. International Journal of Infectious Diseases. 12. e78–e78. 5 indexed citations

16.

Poovorawan, Yong, et al.. (2008). Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age. Vaccine. 26(12). 1535–1540. 11 indexed citations

17.

Ruelle, Jean, et al.. (2008). P.051 Performances and comparative evaluation of the automated VERSANT® HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. Journal of Clinical Virology. 44. S28–S28.

18.

Prymula, Roman, Marie‐Pierre David, Inge Lefevre, & Igor Kohl. (2007). The Immunogenicity and Reactogenicity of a New DTPw-HBV Vaccine as a Primary and Booster Vaccination Dourse in Healthy Infants. Human Vaccines. 3(4). 121–126. 5 indexed citations

19.

Ortega‐Barría, Eduardo, et al.. (2007). The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: Results from four phase III multicenter trials across three continents. Vaccine. 25(50). 8432–8440. 9 indexed citations

20.

Gatchalian, Salvacion, Inge Lefevre, Marie‐Pierre David, et al.. (2005). A New DTPw-HBV/Hib Vaccine is Immunogenic and Safe when Administered According to the EPI (Expanded Programme for Immunization) Schedule and Following Hepatitis B Vaccination at Birth. Human Vaccines. 1(5). 198–203. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact